{"product_id":"bowel-problems-and-quality-of-life-after-colon-cancer-surgery-what-patients-should-know","title":"Bowel Problems and Quality of Life After Colon Cancer Surgery: What Patients Should Know","description":"\u003cp\u003eAfter colon cancer surgery, more than one in five patients experience troublesome bowel symptoms similar to the \"low anterior resection syndrome\" (LARS) seen after rectal cancer surgery — and these symptoms significantly damage their quality of life. This large Dutch study of 1,495 patients found that women and patients who previously had a temporary stoma were at highest risk. Colon cancer survivors with major LARS symptoms reported quality-of-life scores as poor as those reported by rectal cancer patients, suggesting doctors need to discuss these risks before surgery and monitor patients afterward.\u003c\/p\u003e\n\n\u003ch1\u003eBowel Problems and Quality of Life After Colon Cancer Surgery: What Patients Should Know\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-findings\"\u003eKey Findings: What the Researchers Discovered\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#risk-factors\"\u003eRisk Factors for Bowel Complaints After Colon Surgery\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#quality-of-life\"\u003eImpact on Quality of Life\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#why-it-happens\"\u003eWhy Do These Symptoms Occur?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn a study of 1,495 patients, 20.9% of colon cancer survivors had major LARS-like bowel symptoms.\u003c\/li\u003e\n\u003cli\u003eMajor LARS symptoms lowered quality-of-life scores as much in colon cancer patients as in rectal cancer patients.\u003c\/li\u003e\n\u003cli\u003eWomen and patients with a previous temporary stoma were about twice as likely to develop major symptoms.\u003c\/li\u003e\n\u003cli\u003eDoctors should discuss bowel risks before colon surgery and monitor survivors afterward, since symptoms can persist for years.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\u003cp\u003eSurvivors of colorectal cancer often face long-term side effects that can last for years after their treatment ends. These include troublesome abdominal complaints, depressive symptoms, and fatigue. For many patients, these persistent issues significantly affect their physical and social functioning — the everyday activities that define quality of life.\u003c\/p\u003e\n\n\u003cp\u003eIn patients treated for \u003cstrong\u003erectal cancer\u003c\/strong\u003e (cancer of the lower part of the large intestine), these postoperative bowel complaints are well-documented and are collectively known as \u003cstrong\u003elow anterior resection syndrome (LARS)\u003c\/strong\u003e. Studies have shown LARS affects 60–90% of rectal cancer patients.\u003c\/p\u003e\n\n\u003cp\u003eHowever, very little research has focused on whether patients who undergo surgery for \u003cstrong\u003ecolon cancer\u003c\/strong\u003e (cancer in the upper parts of the large intestine) experience similar problems.\u003c\/p\u003e\n\n\u003cp\u003ePrevious research had hinted at the issue. One recent cross-sectional study showed that patients treated for sigmoid tumours (the S-shaped section of the colon just before the rectum) experience post-treatment symptoms even years after the event. Another study found that patients who had a right hemicolectomy (removal of the right side of the colon) experience persistent diarrhoea in the first 3 months after surgery, leading to a decreased quality of life.\u003c\/p\u003e\n\n\u003cp\u003eWhat has been lacking is a large, systematic study looking at the full range of bowel symptoms after colon cancer surgery and their impact on how patients live their lives. The authors of this study also noted that colorectal surgeons often do not have a thorough understanding of the problems patients face after colonic surgery.\u003c\/p\u003e\n\n\u003cp\u003eThis study set out to answer a simple but important question: \u003cstrong\u003eHow common are functional bowel complaints after colon cancer surgery, and how do they affect quality of life compared with what we already know about rectal cancer patients?\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/h2\u003e\n\u003cp\u003eThe researchers carried out a multicentre, retrospective cross-sectional study in the south-east of the Netherlands. They invited all patients who had undergone surgery for Stage 1–3 colorectal cancer between January 2008 and December 2015 at six hospitals to participate. Patients who had a temporary colostomy or ileostomy could participate if their stoma had been closed for more than a year, to allow bowel function to stabilise.\u003c\/p\u003e\n\n\u003cp\u003eThe six participating hospitals were:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eVieCuri Medical Centre, Venlo\u003c\/li\u003e\n  \u003cli\u003eLaurentius Hospital, Roermond\u003c\/li\u003e\n  \u003cli\u003eZuyderland Hospital, Sittard and Heerlen\u003c\/li\u003e\n  \u003cli\u003eMaxima Medical Centre, Veldhoven\u003c\/li\u003e\n  \u003cli\u003eMaastricht University Medical Centre\u003c\/li\u003e\n  \u003cli\u003eCatharina Hospital, Eindhoven\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePatients were excluded if they had died, were under 18 years old, had disseminated or recurrent disease, had inadequate Dutch language skills, or had intellectual disability or dementia. Patients with irresectable disease or locally excised tumours (such as those removed by transanal endoscopic microsurgery) were also excluded.\u003c\/p\u003e\n\n\u003ch3\u003eQuestionnaires Used\u003c\/h3\u003e\n\u003cp\u003ePatients received a letter with information about the study, an informed consent form, and three questionnaires. They could complete them at home and return them free of charge. Non-responders received a reminder after 8 weeks.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers used three validated tools to measure bowel function and quality of life:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe LARS Score.\u003c\/strong\u003e This internationally validated tool measures bowel dysfunction after rectal cancer surgery. It consists of five questions with a total score ranging from 0 to 42 points. Patients are classified into three categories:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo LARS:\u003c\/strong\u003e 0–20 points\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMinor LARS:\u003c\/strong\u003e 21–29 points\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMajor LARS:\u003c\/strong\u003e 30–42 points\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe EORTC QLQ-C30.\u003c\/strong\u003e This questionnaire consists of 30 questions measuring functional scales (physical, role, emotional, cognitive, and social functioning), global quality of life, and symptoms (such as fatigue, pain, and diarrhoea). A high functional score means better function; a high symptom score means more symptoms.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe EORTC QLQ-CR29.\u003c\/strong\u003e This questionnaire is specifically designed for colorectal cancer patients. It includes 29 items addressing gastrointestinal symptoms, side effects of chemotherapy, defaecation problems, pain, problems with urination, and separate items on sexual function for men and women.\u003c\/p\u003e\n\n\u003ch3\u003eWhat Data Were Collected\u003c\/h3\u003e\n\u003cp\u003eThe researchers also gathered clinical data from electronic patient files, including:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eGender and age\u003c\/li\u003e\n  \u003cli\u003eMarital status\u003c\/li\u003e\n  \u003cli\u003eBody mass index (BMI)\u003c\/li\u003e\n  \u003cli\u003eAmerican Society of Anesthesiologists (ASA) score (a measure of overall health and surgical risk)\u003c\/li\u003e\n  \u003cli\u003eComplications (classified using the Clavien–Dindo scale)\u003c\/li\u003e\n  \u003cli\u003eTumour stage and location\u003c\/li\u003e\n  \u003cli\u003eTreatment received and time since surgery\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"key-findings\"\u003eKey Findings: What the Researchers Discovered\u003c\/h2\u003e\n\u003ch3\u003eWho Was Included\u003c\/h3\u003e\n\u003cp\u003eA total of 5,824 patients were operated on for colorectal cancer between January 2008 and December 2015. Of these, 2,136 were eligible for the study and received an invitation letter. The reasons for exclusion were:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eDeath (n = 850)\u003c\/li\u003e\n  \u003cli\u003eMetastatic disease (n = 1,288)\u003c\/li\u003e\n  \u003cli\u003eStage 4 tumours (n = 218)\u003c\/li\u003e\n  \u003cli\u003ePresence of a colostomy or ileostomy (n = 897)\u003c\/li\u003e\n  \u003cli\u003eLocal excision (n = 120)\u003c\/li\u003e\n  \u003cli\u003eRelapse of disease (n = 192)\u003c\/li\u003e\n  \u003cli\u003eMental disability (n = 84)\u003c\/li\u003e\n  \u003cli\u003eMissing address (n = 11)\u003c\/li\u003e\n  \u003cli\u003ePoor Dutch language proficiency (n = 28)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOf the 2,136 patients invited, \u003cstrong\u003e82.6% completed and returned the questionnaires\u003c\/strong\u003e, while 12.6% returned an unfilled questionnaire with reasons for declining. This left \u003cstrong\u003e1,495 patients for analysis\u003c\/strong\u003e: 1,145 with colon cancer and 350 with rectal cancer.\u003c\/p\u003e\n\n\u003ch3\u003eDifferences Between Colon and Rectal Cancer Patients\u003c\/h3\u003e\n\u003cp\u003eAlmost all baseline characteristics differed significantly between the two groups. Rectal cancer patients were younger (median age 71 versus 73 years, P \u0026lt; 0.001), had more early-stage (Stage 0–1) tumours (44.9% versus 27.6%, P \u0026lt; 0.001), and had fewer comorbidities (ASA Grade I: 29.2% versus 24.0%, P \u0026lt; 0.001). Time since surgery was longer for rectal patients (median 5 versus 4 years, P \u0026lt; 0.001), and they were much more likely to have had a temporary diverting stoma (78.9% versus 11.1%, P \u0026lt; 0.001) and neoadjuvant therapy (radiotherapy before surgery: 72% versus 1.7%, P \u0026lt; 0.001).\u003c\/p\u003e\n\n\u003cp\u003eMore rectal cancer patients underwent open surgery (55.3% versus 43.0%, P \u0026lt; 0.001), and the types of anastomosis (the surgical connection joining the remaining bowel) differed significantly between groups. There was no significant difference in the use of adjuvant chemotherapy (P = 0.207).\u003c\/p\u003e\n\n\u003ch3\u003ePrevalence of LARS Symptoms\u003c\/h3\u003e\n\u003cp\u003eThe headline finding: \u003cstrong\u003eMajor LARS was observed in 20.9% (n = 237) of patients after colon cancer surgery\u003c\/strong\u003e, compared with 55.4% (n = 194) of patients after rectal cancer surgery. This means \u003cstrong\u003emore than 1 in 5 colon cancer survivors\u003c\/strong\u003e had symptoms severe enough to be classified as \"major LARS.\"\u003c\/p\u003e\n\n\u003cp\u003eMinor LARS was distributed more evenly between the groups:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eColon cancer patients:\u003c\/strong\u003e 19.5% (n = 221) experienced minor LARS\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRectal cancer patients:\u003c\/strong\u003e 20.7% (n = 73) experienced minor LARS\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eWhen the researchers broke down the results by the specific type of surgery performed, the percentage of patients reporting major LARS was:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRectal resection:\u003c\/strong\u003e 51.2%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSigmoid resection:\u003c\/strong\u003e 20.4%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLeft hemicolectomy:\u003c\/strong\u003e 14.3%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRight hemicolectomy:\u003c\/strong\u003e 22.3%\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis is a striking finding. Sigmoid resection (removing part of the lower colon) was associated with as many major LARS symptoms as right hemicolectomy (removing part of the upper colon), and both were significantly more common than after left hemicolectomy.\u003c\/p\u003e\n\n\u003ch2 id=\"risk-factors\"\u003eRisk Factors for Bowel Complaints After Colon Surgery\u003c\/h2\u003e\n\u003cp\u003eThe researchers performed both univariate (single-factor) and multivariate (multiple-factor) analyses to identify which patients were most likely to develop major LARS-like symptoms after colon cancer surgery.\u003c\/p\u003e\n\n\u003cp\u003eIn the initial univariate analysis, colon cancer patients with major LARS were more likely to:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eBe female (P \u0026lt; 0.001)\u003c\/li\u003e\n  \u003cli\u003eHave had a previous temporary stoma (P = 0.012)\u003c\/li\u003e\n  \u003cli\u003eHave had mild postsurgical complications according to the Clavien–Dindo scale (P = 0.037)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eInterestingly, patients with a tumour in the transverse colon, splenic flexure, or descending colon (P = 0.061) and patients who received adjuvant chemotherapy (P = 0.010) reported \u003cstrong\u003efewer\u003c\/strong\u003e major LARS symptoms.\u003c\/p\u003e\n\n\u003cp\u003eIn the multivariate analysis, four factors stood out as independent predictors:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFemale gender:\u003c\/strong\u003e Women were nearly twice as likely as men to suffer from major LARS symptoms (OR = 1.88, CI 1.392–2.528, P \u0026lt; 0.001).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePrevious diverting stoma:\u003c\/strong\u003e Patients who had a temporary stoma in the past were also nearly twice as likely to develop major LARS symptoms (OR = 1.84, CI 1.14–2.97, P = 0.012).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLeft hemicolectomy:\u003c\/strong\u003e Patients who underwent a left hemicolectomy (removal of the left side of the colon) were \u003cem\u003eless\u003c\/em\u003e likely to suffer from major LARS symptoms (OR = 0.55, CI 0.31–0.97, P = 0.040).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAdjuvant chemotherapy:\u003c\/strong\u003e Patients who received chemotherapy after surgery were also \u003cem\u003eless\u003c\/em\u003e likely to suffer from major LARS symptoms (OR = 0.64, CI 0.45–0.89, P = 0.010).\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eFor patients, this means women and those who needed a temporary stoma during their treatment journey should be especially aware that bowel symptoms may persist — and should raise these concerns with their medical team.\u003c\/p\u003e\n\n\u003ch2 id=\"quality-of-life\"\u003eImpact on Quality of Life\u003c\/h2\u003e\n\u003cp\u003eThe study clearly demonstrated that major LARS symptoms significantly damage quality of life. On average, patients with major LARS symptoms reported a \u003cstrong\u003epoorer global quality of life score of 70.9 (SD 19.4)\u003c\/strong\u003e compared with \u003cstrong\u003e80.8 (SD 17.1)\u003c\/strong\u003e for patients with no or minor LARS symptoms.\u003c\/p\u003e\n\n\u003cp\u003eThe difference in quality of life between the no\/minor LARS and major LARS groups was most dramatic in specific surgical groups:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eAfter (sub)total colectomy (removal of all or most of the colon): a difference of \u003cstrong\u003e−26.8 points\u003c\/strong\u003e in mean QoL score\u003c\/li\u003e\n  \u003cli\u003eAfter right hemicolectomy: a difference of \u003cstrong\u003e−13.3 points\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eGeneral Quality of Life Measures (EORTC QLQ-C30)\u003c\/h3\u003e\n\u003cp\u003eIn multivariate analysis adjusting for other factors, colon cancer patients with major LARS symptoms reported:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLower emotional functioning\u003c\/strong\u003e (OR 0.98, CI 0.98–0.99, P = 0.006)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMore pain\u003c\/strong\u003e (OR 1.01, CI 1.00–1.02, P = 0.034)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMore insomnia\u003c\/strong\u003e (OR 1.006, CI 1.00–1.01, P = 0.047)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMore diarrhoea\u003c\/strong\u003e (OR 1.04, CI 1.03–1.05, P \u0026lt; 0.001) — the strongest association of all general symptoms\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eColorectal-Specific Quality of Life (EORTC QLQ-CR29)\u003c\/h3\u003e\n\u003cp\u003eOn the colorectal-specific questionnaire, patients with major LARS symptoms reported:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLess anxiety about the future\u003c\/strong\u003e (OR 1.016, CI 1.01–1.02, P \u0026lt; 0.001)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHigher stool frequency\u003c\/strong\u003e (OR 1.05, CI 1.04–1.06, P \u0026lt; 0.001)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMore incontinence\u003c\/strong\u003e (OR 1.03, CI 1.02–1.04, P \u0026lt; 0.001)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMore problems controlling flatulence\u003c\/strong\u003e (OR 1.02, CI 1.01–1.03, P \u0026lt; 0.001)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePerhaps the most important finding for patients is this: \u003cstrong\u003eThere was no significant difference in quality of life between colon and rectal cancer patients with major LARS symptoms (P = 0.138).\u003c\/strong\u003e In other words, a colon cancer patient with major bowel complaints suffers just as much as a rectal cancer patient with major LARS.\u003c\/p\u003e\n\n\u003ch2 id=\"why-it-happens\"\u003eWhy Do These Symptoms Occur?\u003c\/h2\u003e\n\u003cp\u003eThe researchers discussed several possible explanations for why colon cancer surgery can lead to LARS-like symptoms. The underlying causes are likely multifactorial (involving multiple mechanisms at once).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLoss of water and electrolyte absorption.\u003c\/strong\u003e The colon's primary job is to absorb water and electrolytes from digested food. When part of the colon is removed, there is less absorptive capacity remaining. This predisposes patients to more liquid stool, increased bowel frequency, excess gas, and a higher risk of faecal incontinence.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eReduced reservoir function.\u003c\/strong\u003e The rectum acts as a storage chamber for stool before defecation. In a sigmoid resection, the rectum may be incorporated into the anastomosis (the surgical connection), which can reduce its reservoir function. This explains why sigmoid resection patients had a prevalence of major LARS symptoms (20.4%) close to that of right hemicolectomy patients (22.3%). In contrast, because the anastomosis in a left-sided colonic resection is colo-colonic (colon connected to colon), the reservoir function of the rectum is spared, and functional complaints are less likely — which was indeed observed (14.3%).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDifferences between right and left resections.\u003c\/strong\u003e Previous studies have shown significantly more abdominal complaints after right-sided than left-sided colonic resections, consistent with the differing absorptive functions of different colon segments.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\u003cp\u003eThis study is the first to raise awareness that LARS-like symptoms occur after surgery for colon cancer, not just after rectal cancer surgery. The authors were explicit that the effect on quality of life is just as severe.\u003c\/p\u003e\n\n\u003cp\u003eSeveral practical implications follow for patients and clinicians:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePre-surgical counselling.\u003c\/strong\u003e Colorectal cancer specialists should inform patients facing colon cancer surgery that they may experience long-term bowel dysfunction, including urgency, frequent bowel movements, gas, and incontinence. Until now, these risks have typically been discussed mainly with rectal cancer patients.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePost-surgical monitoring.\u003c\/strong\u003e Doctors should actively ask colon cancer survivors about bowel function during follow-up visits. Patients may not volunteer this information out of embarrassment, or may assume it is a normal consequence of surgery that cannot be improved.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTreatment options.\u003c\/strong\u003e Patients with major LARS-like symptoms after colon surgery deserve the same attention and treatment options as rectal cancer patients with LARS. These may include dietary adjustments, medications to slow bowel transit or bind stool, pelvic floor physiotherapy, and in severe cases, interventions such as sacral nerve stimulation. The study did not evaluate these treatments, but it highlights the need for them.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe surprising chemotherapy finding.\u003c\/strong\u003e One puzzling result was that patients who received adjuvant chemotherapy (post-operative chemotherapy) reported \u003cem\u003efewer\u003c\/em\u003e major LARS symptoms. The authors noted this finding but did not have a clear physiological explanation. It is possible that patients receiving chemotherapy had more intense follow-up and nutritional support, or the finding may be due to selection bias — for example, patients with more aggressive tumours may have had different types of surgery. Patients should not interpret this as a reason to seek chemotherapy; it is simply an association observed in this study.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\u003cp\u003eAs with all research, this study has limitations that patients should understand when interpreting the results.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRetrospective and cross-sectional design.\u003c\/strong\u003e The study looked back at patients at one point in time rather than following them forward. This means the researchers cannot establish cause and effect — they can only show associations. For example, the finding that chemotherapy was associated with fewer LARS symptoms could be due to unmeasured factors rather than the chemotherapy itself.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSelf-reported symptoms.\u003c\/strong\u003e All bowel symptoms and quality-of-life data were self-reported through questionnaires. Patients' recollection and reporting can vary, and there is no objective measurement of bowel function.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSelection bias.\u003c\/strong\u003e Although the response rate was high (82.6%), the 12.6% of patients who returned unfilled questionnaires may have differed systematically from those who participated. It is possible that patients with more severe symptoms were either more or less likely to respond.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNo baseline data.\u003c\/strong\u003e The researchers did not have pre-surgery bowel function data, so they cannot determine how much of the reported bowel dysfunction was caused by the cancer surgery versus pre-existing bowel habits or age-related changes.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNot population-wide.\u003c\/strong\u003e Patients with permanent stomas, metastatic disease, and recurrent disease were excluded. This means the prevalence figures may not apply to the entire colon cancer survivor population. Also, all hospitals were in one region of the Netherlands, so results may not generalise to other countries with different surgical practices.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\u003cp\u003eBased on this study, here is practical advice for patients facing or recovering from colon cancer surgery:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about bowel function before surgery.\u003c\/strong\u003e When discussing surgery with your surgeon, ask specifically: \"What bowel symptoms might I have after this operation, and how long might they last?\" This study shows that troublesome symptoms can persist for years — not just the first few months.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eReport symptoms after surgery.\u003c\/strong\u003e Do not dismiss ongoing bowel problems as something you have to live with. Bring them up at follow-up appointments. The study shows bowel complaints are common and that effective discussion can lead to better management.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your risk.\u003c\/strong\u003e The study found women and patients who had a temporary stoma during treatment are at higher risk of developing major LARS-like symptoms after colon surgery. If this applies to you, be especially proactive in seeking help.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand that symptoms vary by surgery type.\u003c\/strong\u003e Major bowel symptoms were seen in 14.3% of patients after left hemicolectomy, 20.4% after sigmoid resection, and 22.3% after right hemicolectomy. Even the \"lowest risk\" group still had a meaningful chance of troublesome symptoms.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eQuality of life matters.\u003c\/strong\u003e If bowel symptoms are interfering with your daily activities, sleep, or emotional wellbeing, know that this is not trivial — the study shows a substantial drop in quality of life. There is no shame in asking for help. Treatments exist, even if they were not the focus of this study.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider what you eat.\u003c\/strong\u003e While this study did not test dietary interventions, the mechanism it describes (reduced water absorption in the remaining colon) suggests that dietary adjustments to manage stool consistency may be beneficial. Discuss this with your doctor or a dietitian specialising in colorectal surgery recovery.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat are LARS-like symptoms after colon cancer surgery?\u003c\/h3\u003e\n\u003cp\u003eLARS-like symptoms include urgency, frequent bowel movements, excess gas, and faecal incontinence. In a Dutch study of 1,495 patients, more than one in five colon cancer survivors had major symptoms that significantly damaged their quality of life. These problems can persist for years after surgery, not just the first few months.\u003c\/p\u003e\n\u003ch3\u003eHow common are bowel problems after colon cancer surgery?\u003c\/h3\u003e\n\u003cp\u003eIn a study of 1,495 colorectal cancer patients, 20.9% of colon cancer patients had major LARS symptoms and 19.5% had minor symptoms. So roughly two in five colon cancer survivors experienced some degree of LARS-like bowel dysfunction. Rectal cancer patients had major LARS in 55.4% of cases, but colon cancer patients were still frequently affected.\u003c\/p\u003e\n\u003ch3\u003eWho is at higher risk for major bowel symptoms after colon cancer surgery?\u003c\/h3\u003e\n\u003cp\u003eWomen were nearly twice as likely as men to have major LARS symptoms, and patients who previously had a temporary stoma were also nearly twice as likely. Patients who had a left hemicolectomy or adjuvant chemotherapy reported fewer major symptoms. If you are female or had a stoma, be especially aware and discuss symptoms with your team.\u003c\/p\u003e\n\u003ch3\u003eShould I discuss bowel risks before colon cancer surgery?\u003c\/h3\u003e\n\u003cp\u003eYes. The study's authors advise that surgeons should inform patients about the possibility of long-term bowel dysfunction, including urgency, frequent stools, gas, and incontinence. Until now, these risks were mainly discussed with rectal cancer patients. Before surgery, ask your surgeon what bowel symptoms you might have and how long they might last.\u003c\/p\u003e\n\u003ch3\u003eWhat treatments are available for LARS-like symptoms after colon surgery?\u003c\/h3\u003e\n\u003cp\u003eThe study did not evaluate treatments, but it says patients with major LARS-like symptoms deserve the same attention and options as rectal cancer patients. These may include dietary adjustments, medications to slow bowel transit or bind stool, pelvic floor physiotherapy, and in severe cases, sacral nerve stimulation. Discuss these options with your healthcare team.\u003c\/p\u003e\n\u003ch3\u003eWhy does colon cancer surgery cause bowel symptoms?\u003c\/h3\u003e\n\u003cp\u003eRemoving part of the colon reduces its ability to absorb water and electrolytes, leading to looser stool, more frequent bowel movements, gas, and incontinence. In sigmoid resection, the rectum's reservoir function may also be reduced. Left hemicolectomy spares the rectum, which likely explains why that group had fewer major symptoms.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Functional bowel complaints and quality of life after surgery for colon cancer\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e M. van Heinsbergen, N. den Haan, A. J. Maaskant-Braat, J. Melenhorst, E. H. Belgers, J. W. Leijtens, J. G. Bloemen, H. J. Rutten, N. D. Bouvy, M. L. Janssen-Heijnen, and J. L. Konsten\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Colorectal Disease, 22(2), 136–145\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication date:\u003c\/strong\u003e February 1, 2020 (accepted July 9, 2019; published online August 9, 2019)\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.1111\/codi.14818\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eInstitutions:\u003c\/strong\u003e Department of Surgery, VieCuri Medical Centre, Venlo; Maxima Medical Centre, Veldhoven; Maastricht University Medical Centre+; Zuyderland Medical Centre, Heerlen; Laurentius Medical Centre, Roermond; Catharina Hospital, Eindhoven; and GROW School for Oncology and Developmental Biology, Maastricht University, The Netherlands.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It does not provide individual medical advice. Patients should consult their healthcare team about their specific situation.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47400024998044,"sku":null,"price":0.0,"currency_code":"RUB","in_stock":true}],"url":"https:\/\/diagnosticdetectives.ru\/products\/bowel-problems-and-quality-of-life-after-colon-cancer-surgery-what-patients-should-know","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}